Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

38.04 +0.09 (+0.24%)

Delayed Quote Updated: 2:46 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

August 05, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential ↗

July 26, 2025

Harmony Biosciences (HRMY) is undervalued with strong fundamentals—low P/E, high profitability, solid financials, and robust growth, making it a prime value investing opportunity.

Via Chartmill

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

July 22, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Where Harmony Biosciences Hldgs Stands With Analysts ↗

June 02, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Harmony Biosciences's Earnings: A Preview ↗

May 05, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation ↗

July 19, 2025

Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical...

Via Chartmill

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

July 15, 2025

From Harmony Biosciences

Via Business Wire

6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know ↗

July 10, 2025

Via Benzinga

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals ↗

July 02, 2025

HARMONY BIOSCIENCES (HRMY) is an undervalued pharmaceutical stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors ↗

June 27, 2025

HARMONY BIOSCIENCES (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical...

Via Chartmill

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

June 11, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock in the Pharmaceutical Sector ↗

June 11, 2025

Harmony Biosciences (HRMY) presents a compelling value opportunity with strong profitability, financial health, and growth—all at an attractive valuation.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock at a Reasonable Valuation ↗

June 06, 2025

Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the pharmaceuticals sector.

Via Chartmill

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

June 05, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

June 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings ([NASDAQ:HRMY](https://www.chartmill.com/stock/quote/HRMY/profile)) – A Strong Growth Stock with Technical Breakout Potential ↗

May 29, 2025

Harmony Biosciences (HRMY) shows strong growth, profitability, and a bullish technical pattern, making it a stock worth watching in the pharmaceuticals sector.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals ↗

May 21, 2025

Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors.

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors ↗

May 15, 2025

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks.

Via Chartmill

Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (13 Ratings) ↗

May 06, 2025

Via Benzinga

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance

May 06, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock ↗

May 02, 2025

Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate ↗

April 30, 2025

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 29, 2025

Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

April 29, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. ↗

April 24, 2025

Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...

Via Chartmill

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views ↗

April 08, 2025

Via Benzinga

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

April 08, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.